Frequency of elevated Hepatocellular Carcinoma (HCC) biomarkers in patients with advanced hepatitis C

American Journal of Gastroenterology

Volumn 107, Issue 1, 2012, Pages 64-74

  Sterling, Richard K ^a   Wright, Elizabeth C ^b   Morgan, Timothy R ^c,d   Seeff, Leonard B ^b   Hoefs, John C ^c   Di Bisceglie, Adrian M ^e   Dienstag, Jules L ^f,g   Lok, Anna S ^h  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN L3; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC HEPATITIS; FEMALE; GENDER; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RACE;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN ISOFORMS; PROTEIN PRECURSORS; PROTHROMBIN;

EID: 84855433060     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.312     Document Type: Article

References (35)

1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-44.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-34. (Pubitemid 39423367)
3. Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008; 121: 119-26. (Pubitemid 351199465)
4. Santi V, Trevisani F, Gramenzi A et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-7.
5. Ikeda K, Saitoh S, Koida I et al. Imaging diagnosis of small hepatocellular carcinoma. Hepatology 1994; 20: 82-7. (Pubitemid 24196494)
6. Oka H, Tamori A, Kuroki T et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-6.
7. Takayasu K, Furukawa H, Wakao F, et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol 1995; 164: 885-90.
8. Ebara M, Ohto M, Watanabe Y et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology 1986; 159: 371-7.
9. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 1939; author reply 1940-1.
10. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alphafetoprotein levels in patients with chronic hepatitis B. Cancer 1989; 64: 2117-20. (Pubitemid 19280413)
11. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998; 93: 2452-6. (Pubitemid 29018554)
12. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-41. (Pubitemid 41111424)
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
14. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127: S113-9. (Pubitemid 39423378)
15. Spangenberg HC, Th imme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006; 26: 385-90. (Pubitemid 44632929)
16. Taketa K, Sekiya C, Namiki M et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990; 99: 508-18. (Pubitemid 20219108)
17. Taketa K, Endo Y, Sekiya C et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993; 53: 5419-23. (Pubitemid 23342160)
18. Oka H, Saito A, Ito K et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378-83. (Pubitemid 34107406)
19. Leerapun A, Suravarapu SV, Bida JP et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007; 5: 394-402; quiz 267. (Pubitemid 46401522)
20. Makuuchi M, Kokudo N, Arii S et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51. (Pubitemid 350182575)
21. Aoyagi Y, Oguro M, Yanagi M et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77: 1781-6. (Pubitemid 26125176)
22. Nomura F, Ishijima M, Kuwa K et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-4. (Pubitemid 29124861)
23. Mita Y, Aoyagi Y, Yanagi M et al. The usefulness of determining desgamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-8. (Pubitemid 28208912)
24. Ishii M, Gama H, Chida N et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000; 95: 1036-40. (Pubitemid 30196743)
25. Hamamura K, Shiratori Y, Shiina iina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma desgamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88: 1557-64. (Pubitemid 30183140)
26. Nakamura S, Nouso K, Sakaguchi K et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-43. (Pubitemid 44337629)
27. Marrero JA, Su GL, Wei W et al. Des-gamma carboxyprothrombin can diff erentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114-21. (Pubitemid 36538688)
28. Sterling RK, Jeff ers L, Gordon F et al. Utility of Lens culinaris agglutininreactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009; 7: 104-13.
29. Marrero JA, Feng Z, Wang Y et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-8.
30. Volk ML, Hernandez JC, Su GL et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007; 3: 79-87. (Pubitemid 47103809)
31. Carr BI, Kanke F, Wise M et al. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52: 776-82.
32. Lok AS, Sterling RK, Everhart JE et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepato cellular carcinoma. Gastroenterology 2010; 138: 493-502.
33. Di Bisceglie AM, Shiff man ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
34. Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.
35. Nguyen MH, Garcia RT, Simpson PW et al. Racial diff erences in Effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-7. (Pubitemid 34810361)